Nicotinamide Riboside Chloride (NR-Cl) Clinical Trials

Size	Price	Qty
25mg	USD 147
100mg	USD 297

Clinical Trials

Multiple clinical trials evaluate nicotinamide riboside chloride across diverse conditions, including aging, lipemia, smooth muscle dysfunction syndrome, ulcerative colitis, acute severe malnutrition, and inadequate milk production in preterm birth. Spanning Phase 1 through Phase 4 as well as non-phased interventional designs, these studies are sponsored by academic, non-profit, and industry entities such as AbbVie and the University of Pittsburgh. Recruitment statuses across this portfolio vary, encompassing completed, actively recruiting, terminated, and planned trials.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05561738	TERMINATED	Ulcerative Colitis	University of Pittsburgh	2024-02-28
NCT06919328	RECRUITING	Healthy Aging	Nutraceuticals Research Institute	2024-10-31
NCT04614714	Not yet recruiting	Preterm Birth\|Inadequate Milk Production	University of California Davis	2024-12	Phase 2\|Phase 3
NCT06333860	Not yet recruiting	Moderate Plaque Psoriasis	AbbVie	2024-05-07	Phase 4
NCT05436106	Not yet recruiting	Psychological Distress\|Stigma Social	Emory University\|National Institute of Nursing Research (NINR)	2024-04	Not Applicable
NCT06380504	Not yet recruiting	Acute Malnutrition Severe\|Malnutrition Child\|Wasting	International Food Policy Research Institute\|Ethiopian Public Health Association\|UNICEF	2024-04-29	Not Applicable
NCT06382688	UNKNOWN	Healthy Aging	Nutraceuticals Research Institute	2023-11-13
NCT06280482	Recruiting	Smooth Muscle Dysfunction Syndrome (SMDS)	The University of Texas Health Science Center Houston	2024-03-06	Phase 1
NCT03501433	COMPLETED	Aging; Lipemia	Iowa State University	2018-02-01

(data from https://clinicaltrials.gov, updated on 2026-08-10)

Check the Nicotinamide Riboside Chloride (NR-Cl) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Nicotinamide riboside chloride functions as a metabolic precursor to elevate intracellular nicotinamide adenine dinucleotide (NAD+) levels, which directly activates the NAD+-dependent deacetylases SIRT1 and SIRT3. This enzymatic pathway enhances mitochondrial oxidative metabolism and cellular bioenergetics, mitigating metabolic abnormalities and cellular stress relevant to clinical conditions such as vascular aging, smooth muscle dysfunction, and inflammatory disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).